Speaker Profile
MS, Founder, CEO, OmicXHealth
Biography
Mythili Subharam is the founder and CEO of OmicXHealth, a software-first precision diagnostics company developing a platform for disease detection using cfDNA methylation and machine learning.
OmicXHealth is built around a “sequence once, analyze many times” architecture that decouples disease detection from the wet-lab assay through software-defined model orchestration. The platform’s initial clinical focus is liver cancer screening and liver disease stratification, where pre-clinical validation has been completed using biobank plasma samples. The company is currently advancing blinded evaluation studies with clinical key opinion leaders while expanding the platform to support additional disease areas.
Mythili has over 25 years of experience building and scaling data-driven software platforms across enterprise and consumer technology, with a focus on translating complex systems into practical, real-world solutions. Her work at OmicXHealth sits at the intersection of genomics, AI, and translational medicine, emphasizing rigorous data analysis, biological interpretability, and clinical relevance.
Talk
AI/ML-Driven Multi-Omic cfDNA Analysis for Disease Detection
OmicXScreen is a software-defined platform decoupling disease detection from the wet-lab assay. Using a single, standardized cfDNA sequencing workflow, the system integrates methylation and fragmentomic signals to orchestrate multiple disease-specific ML models. This enables early detection in high-risk patients and efficient biomarker-driven clinical trial enrollment. Expansion to additional diseases requires no wet-lab assay redesign.
AI and Data Sciences Showcase:
OmicXHealth
OmicXHealth, a software-first precision diagnostics company developing a platform for disease detection using cfDNA methylation and machine learning. The platform’s initial clinical focus is liver cancer screening and liver disease stratification, where pre-clinical validation has been completed using biobank samples. The company is currently advancing blinded validation studies with clinical KOLs while expanding the platform to support additional diseases.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
